Literature DB >> 33205391

The tellurium-based immunomodulator, AS101 ameliorates adjuvant-induced arthritis in rats.

G Halpert1, M Halperin Sheinfeld2, L Monteran2, K Sharif3, A Volkov4, R Nadler5, A Schlesinger6,7, I Barshak4, Y Kalechman2, M Blank1, Y Shoenfeld1,8, H Amital3.   

Abstract

Despite undeniable improvement in the management of rheumatoid arthritis (RA), the discovery of more effective, less toxic and, ideally, less immune suppressive drugs are much needed. In the current study, we set to explore the potential anti-rheumatic activity of the non-toxic, tellurium-based immunomodulator, AS101 in an experimental animal model of RA. The effect of AS101 was assessed on adjuvant-induced arthritis (AIA) rats. Clinical signs of arthritis were assessed. Histopathological examination was used to assess inflammation, synovial changes and tissue lesions. Very late antigen-4 (VLA-4)+ cellular infiltration was detected using immunohistochemical staining. Enzyme-linked immunosorbent assay (ELISA) was used to measure circulating anti-cyclic citrullinated-peptide autoantibody (ACPA) and real-time polymerase chain reaction (PCR) was used to measure the in-vitro effect of AS101 on interleukin (IL)-6 and IL-1β expression in activated primary human fibroblasts. Prophylactic treatment with intraperitoneal AS101 reduced clinical arthritis scores in AIA rats (P < 0·01). AS101 abrogated the migration of active chronic inflammatory immune cells, particularly VLA-4+ cells, into joint cartilage and synovium, reduced the extent of joint damage and preserved joint architecture. Compared to phosphate-buffered saline (PBS)-treated AIA rats, histopathological inflammatory scores were significantly reduced (P < 0·05). Furthermore, AS101 resulted in a marked reduction of circulating ACPA in comparison to PBS-treated rats (P < 0·05). Importantly, AS101 significantly reduced mRNA levels of proinflammatory mediators such as IL-6 (P < 0·05) and IL-1β (P < 0·01) in activated primary human fibroblasts. Taken together, we report the first demonstration of the anti-rheumatic/inflammatory activity of AS101 in experimental RA model, thereby supporting an alternative early therapeutic intervention and identifying a promising agent for therapeutic intervention.
© 2020 British Society for Immunology.

Entities:  

Keywords:  AS101; Adjuvant-induced arthritis; integrins; rheumatoid arthritis; tellurium

Mesh:

Substances:

Year:  2020        PMID: 33205391      PMCID: PMC7874835          DOI: 10.1111/cei.13553

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   5.732


  48 in total

Review 1.  The value of early intervention in RA--a window of opportunity.

Authors:  Ferdinand Breedveld
Journal:  Clin Rheumatol       Date:  2011-02-25       Impact factor: 2.980

2.  Alternatively spliced CS-1 fibronectin isoform and its receptor VLA-4 in rheumatoid arthritis synovium.

Authors:  U Müller-Ladner; M J Elices; J B Kriegsmann; D Strahl; R E Gay; G S Firestein; S Gay
Journal:  J Rheumatol       Date:  1997-10       Impact factor: 4.666

3.  Resolution of inflammation-related apoptotic processes by the synthetic tellurium compound, AS101 following liver injury.

Authors:  Miri Brodsky; Shira Hirsh; Michael Albeck; Benjamin Sredni
Journal:  J Hepatol       Date:  2009-06-06       Impact factor: 25.083

4.  The synthetic tellurium compound, AS101, is a novel inhibitor of IL-1beta converting enzyme.

Authors:  Miri Brodsky; Sigal Yosef; Rushkin Galit; Michael Albeck; Dan L Longo; Amnon Albeck; Benjamin Sredni
Journal:  J Interferon Cytokine Res       Date:  2007-06       Impact factor: 2.607

5.  Redox modulation of adjacent thiols in VLA-4 by AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive state.

Authors:  Adi Layani-Bazar; Itai Skornick; Alain Berrebi; Maor H Pauker; Elad Noy; Alon Silberman; Michael Albeck; Dan L Longo; Yona Kalechman; Benjamin Sredni
Journal:  Cancer Res       Date:  2014-04-03       Impact factor: 12.701

6.  Tellurium compound AS101 ameliorates experimental autoimmune encephalomyelitis by VLA-4 inhibition and suppression of monocyte and T cell infiltration into the CNS.

Authors:  Jun-Ho Lee; Meital Halperin-Sheinfeld; Dolgar Baatar; Mohamed R Mughal; Hyun-Jin Tae; Jie-Wan Kim; Arnell Carter; Ana Lustig; Omri Snir; Gad Lavie; Eitan Okun; Mark P Mattson; Benjamin Sredni; Dennis D Taub
Journal:  Neuromolecular Med       Date:  2013-11-23       Impact factor: 3.843

Review 7.  Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy.

Authors:  Brad Bolon; Marina Stolina; Caroline King; Scot Middleton; Jill Gasser; Debra Zack; Ulrich Feige
Journal:  J Biomed Biotechnol       Date:  2010-12-28

Review 8.  Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab.

Authors:  Sedat Yilmaz; Ismail Simsek
Journal:  Ther Clin Risk Manag       Date:  2013-10-25       Impact factor: 2.423

9.  Rat blood neutrophils express very late antigen 4 and it mediates migration to arthritic joint and dermal inflammation.

Authors:  T B Issekutz; M Miyasaka; A C Issekutz
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

10.  The small tellurium-based compound SAS suppresses inflammation in human retinal pigment epithelium.

Authors:  Rima Dardik; Tami Livnat; Gilad Halpert; Shayma Jawad; Yael Nisgav; Shirley Azar-Avivi; Baoying Liu; Robert B Nussenblatt; Dov Weinberger; Benjamin Sredni
Journal:  Mol Vis       Date:  2016-05-28       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.